Acuta Capital Partners’s Pyxis Oncology PYXS Stock Holding History

Acuta Capital Partners’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-669,158	Closed	-$897K	–	41
2022 Q4	$897K	Hold	669,158	–	–	0.55%	28
2022 Q3	$1.32M	Buy	669,158 +24,009	+4%	+$62.7K	0.57%	32
2022 Q2	$1.53M	Buy	645,149 +445,149	+223%	+$1.19M	0.86%	30
2022 Q1	$808K	Sell	200,000 -477,753	-70%	-$3.49M	0.38%	35
2021 Q4	$7.43M	Buy	+677,753	New	+$7.76M	3.13%	10

Other funds holding PYXS

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acuta Capital Partners's PYXS Position: Q1 2023 in Review

Acuta Capital Partners sold out of Pyxis Oncology (PYXS) in Q1 2023, closing a stake of 669,158 shares — an estimated $897K sold.

Acuta Capital Partners first reported a position in PYXS in Q4 2021 and held it in 5 quarters. The position peaked at $7.43M in Q4 2021. 47 funds tracked by Wall St. Rank hold PYXS as of Q1 2023.

Acuta Capital Partners reported no remaining Pyxis Oncology position as of Q1 2023 after selling out during the quarter.
Acuta Capital Partners sold 669,158 Pyxis Oncology shares in Q1 2023, an estimated $897K.
Acuta Capital Partners first reported a position in Pyxis Oncology in Q4 2021 and held it in 5 quarters.
Acuta Capital Partners's Pyxis Oncology position peaked at $7.43M in Q4 2021.
47 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2023.

Based on Acuta Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.